ECSP088704A - Derivados de tieno-piridina como inhibidores de mek - Google Patents

Derivados de tieno-piridina como inhibidores de mek

Info

Publication number
ECSP088704A
ECSP088704A EC2008008704A ECSP088704A ECSP088704A EC SP088704 A ECSP088704 A EC SP088704A EC 2008008704 A EC2008008704 A EC 2008008704A EC SP088704 A ECSP088704 A EC SP088704A EC SP088704 A ECSP088704 A EC SP088704A
Authority
EC
Ecuador
Prior art keywords
pyridine derivatives
tieno
mek inhibitors
substituted
mapkk
Prior art date
Application number
EC2008008704A
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Jeremy Martin Davis
Barry John Langham
James A Johnson
Martin Clive Hutchings
Sarah Catherine Archibald
Judi Charlotte Neuss
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of ECSP088704A publication Critical patent/ECSP088704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una serie de derivados de tieno[2,3-b]piridina que están sustituidos en la posición 2 con un resto anilino sustituido, que son inhibidores selectivos de las enzimas MEK (MAPKK)humanas, son por consiguiente beneficiosos en medicina, por ejemplo en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, proliferativas (con inclusión de las oncológicas) y nociceptivas
EC2008008704A 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek ECSP088704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0601962.4A GB0601962D0 (en) 2006-01-31 2006-01-31 Therapeutic agents

Publications (1)

Publication Number Publication Date
ECSP088704A true ECSP088704A (es) 2008-09-29

Family

ID=36100789

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008704A ECSP088704A (es) 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek

Country Status (26)

Country Link
US (3) US8283359B2 (es)
EP (1) EP1981892B1 (es)
JP (1) JP5249787B2 (es)
KR (1) KR101446919B1 (es)
CN (1) CN101379067B (es)
AU (1) AU2007211377B2 (es)
BR (1) BRPI0708016B1 (es)
CA (1) CA2640594C (es)
CY (1) CY1115404T1 (es)
DK (1) DK1981892T3 (es)
EA (1) EA016128B1 (es)
EC (1) ECSP088704A (es)
ES (1) ES2471970T3 (es)
GB (1) GB0601962D0 (es)
HR (1) HRP20140503T1 (es)
IL (1) IL192603A (es)
MY (1) MY146387A (es)
NO (1) NO341064B1 (es)
NZ (1) NZ569638A (es)
PL (1) PL1981892T3 (es)
PT (1) PT1981892E (es)
RS (1) RS53342B (es)
SI (1) SI1981892T1 (es)
UA (1) UA95939C2 (es)
WO (1) WO2007088345A1 (es)
ZA (1) ZA200807447B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (en) * 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP5503930B2 (ja) * 2009-09-18 2014-05-28 住友化学株式会社 ３−アミノ−１−ｔｅｒｔ−ブトキシカルボニルピペリジンの精製方法およびそのクエン酸塩
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
EP3696276A1 (en) 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CN111138449B (zh) * 2020-01-15 2022-11-29 四川大学华西医院 双靶向erk1和erk5抑制剂的制备及其抗肿瘤应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of pyrrolopyridine-aniline compounds
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9810385A (pt) 1997-07-01 2000-09-05 Warner Lambert Co Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20030225273A1 (en) 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
MXPA05006367A (es) * 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
CA2528602A1 (en) 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
CA2528603A1 (en) * 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005023818A2 (en) * 2003-09-10 2005-03-17 Gpc Biotech Ag Heterobicyclic compounds as pharmaceutically active agents
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7217723B2 (en) * 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (en) * 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
CA2640594C (en) 2014-12-23
PL1981892T3 (pl) 2014-08-29
US20120329774A1 (en) 2012-12-27
US8283359B2 (en) 2012-10-09
NO20083739L (no) 2008-08-29
DK1981892T3 (da) 2014-06-23
IL192603A0 (en) 2009-02-11
US20090149437A1 (en) 2009-06-11
KR20080095870A (ko) 2008-10-29
BRPI0708016B1 (pt) 2021-07-06
SI1981892T1 (sl) 2014-07-31
JP2009525317A (ja) 2009-07-09
JP5249787B2 (ja) 2013-07-31
CY1115404T1 (el) 2017-01-04
BRPI0708016A2 (pt) 2011-05-17
GB0601962D0 (en) 2006-03-15
NZ569638A (en) 2010-08-27
IL192603A (en) 2013-12-31
CN101379067A (zh) 2009-03-04
ES2471970T3 (es) 2014-06-27
HRP20140503T1 (hr) 2014-07-04
CA2640594A1 (en) 2007-08-09
US8394822B2 (en) 2013-03-12
AU2007211377A1 (en) 2007-08-09
US8604051B2 (en) 2013-12-10
ZA200807447B (en) 2009-11-25
EA200801684A1 (ru) 2009-04-28
EP1981892B1 (en) 2014-03-12
RS53342B (sr) 2014-10-31
AU2007211377B2 (en) 2012-03-01
KR101446919B1 (ko) 2014-10-07
PT1981892E (pt) 2014-06-23
HK1125924A1 (en) 2009-08-21
EP1981892A1 (en) 2008-10-22
CN101379067B (zh) 2011-03-23
NO341064B1 (no) 2017-08-14
MY146387A (en) 2012-08-15
EA016128B1 (ru) 2012-02-28
WO2007088345A1 (en) 2007-08-09
UA95939C2 (en) 2011-09-26
US20130150573A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
ECSP088704A (es) Derivados de tieno-piridina como inhibidores de mek
CO6270229A2 (es) Derivados de tiazol fusionados como inhibidores de quinasa
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
MX356086B (es) Produccion de acidos grasos y derivados de los mismos.
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
MX2009009371A (es) Produccion mejorada de derivados de acidos grasos.
DK2021577T3 (da) Konfigurerbart borehulszoneisolationssystem og tilhørende fremgangsmåder
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
EP2508600A4 (en) MUTANT ENZYM AND ITS APPLICATION
PT2348023E (pt) Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
DK2254996T3 (da) Lipaser med høj specificitet for kortkædede fedtsyrer og anvendelser deraf
DK2229391T3 (da) Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
EP1984061A4 (en) COAXIAL PTA BALLOON
HRP20150474T1 (xx) PIRIDINOM I KINOLINOM SUPSTITUIRANI PIROLO[1,2-b]PIRAZOL MONOHIDRAT KAO INHIBITOR TGF-BETA
ATE429320T1 (de) Medizinische vorrichtung und herstellungsverfahren dafür
SMT201400013B (it) Attivatori di ampk tieno[2,3-B] piridina dione e loro impieghi terapeutici
BR112014001075A2 (pt) sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
DK2046797T3 (da) Furo-[3,2-b]pyrrol-3-onderivativer og deres anvendelse som cysteinylproteinaseinhibitorer
BRPI0719166A2 (pt) Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
EP2084719A4 (en) SUPERCONDUCTING ARTICLES AND MANUFACTURING PROCESS
IS8178A (is) Oxazólidinon fúkalyf setin með sýklóprópýlhóp og afleiður þeirra
CO6710901A2 (es) Método de vitrificación de superficie con nitrógeno líquido